CoChat
Sign Up
Cited by 7Cholangiocarcinoma and Gallbladder Cancer StudiesFibroblast Growth Factor ResearchPediatric Hepatobiliary Diseases and Treatments

The DOI matches its Crossref record.

76MO Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial

Open access
Park, J.O., Wai Meng, D.T., Hollebecque, A., Borad, M., Goyal, L., Schram, A., Cassier, P., Kamath, S.D., Dotan, E., Kim, R., Sahai, V., Liao, C-Y., Millward, M., Roda Perez, D., Blakesley, R., Wolf, B., Subbiah, V., Kelley, R.K., Oh, D-Y.·2022·Annals of Oncology
DOI 10.1016/j.annonc.2022.10.112
Open this paper in CoChat — free account

Overview

Integrity signals

Registry

Crossref · 10.1016/j.annonc.2022.10.112

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cited by

Sorted by citations

Related

Metadata

Authors
Park, J. O., Wai Meng, D. T., Hollebecque, A., Borad, M., Goyal, L., Schram, A., Cassier, P., Kamath, S. D., Dotan, E., Kim, R., Sahai, V., Liao, C.-Y., Millward, M., Roda Perez, D., Blakesley, R., Wolf, B., Subbiah, V., Kelley, R. K., & Oh, D.-Y.
Affiliations
  • Samsung Medical Center (KR)
  • Institut Gustave Roussy (FR)
  • Mayo Clinic (US)
  • Massachusetts General Hospital (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • Centre Léon Bérard (FR)
  • Cleveland Clinic (US)
  • Fox Chase Cancer Center (US)
  • University of South Florida (US)
  • University of Michigan (US)
  • University of Chicago (US)
  • The University of Western Australia (AU)
  • Relay Therapeutics (United States) (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • University of California, San Francisco (US)
  • Seoul National University Hospital (KR)
ORCID
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2022-11
Volume
33
Pages
S1461-S1462
ISSN
0923-7534 (ISSN-L)
DOI
10.1016/j.annonc.2022.10.112
OpenAlex
W4310754092
Cited by
7
References
0
Citations by year
2025: 1 · 2024: 3 · 2023: 3
FWCI
1.68
Type
journal article
Language
en
Open access
Licence
Locations
Annals of Oncology (publishedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
Keywords
RLY-4008, FGFR2 inhibitor, FGFR2 fusion, FGFR2 rearrangement, cholangiocarcinoma, off-target toxicity, objective response rate, duration of response

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review